ArticleFrontiers in oncology2023

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.

Tamara Chitanava et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.